Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs

Abstract

Initiation of MS disease-modifying drugs was associated with substantial significant medical and indirect savings for employees with MS. Study findings should be considered in the context of the study limitations (e.g., analytic focus on employees with at least 12-month follow-up; lack of clinical detail on MS severity).